Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow® Technology.
Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
Key data on economic impact of Bronchiolitis Obliterans Syndrome (BOS) presented at ISHLT 2021
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies.
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
